文献速递消化道肿瘤与早癌消化内镜

丹麦筛查项目中粪便免疫化学检测阳性患者选择结肠胶囊内镜或结肠镜检查与默认结肠镜检查的比较:平行组随机对照试验

Choice of colon capsule or colonoscopy versus default colonoscopy in FIT positive patients in the Danish screening programme: a parallel group randomised controlled trial.
PubMed 文献 · Gut · 2025-09-08

在丹麦结直肠癌筛查项目中,粪便免疫化学检测(FIT)阳性者被随机分为可选择结肠胶囊内镜(CCE)或结肠镜的研究组与仅接受结肠镜的对照组。两组进展期肿瘤检出率相似(研究组0.67% vs 对照组0.64%),但研究组中初始选择CCE者69.9%后续转诊结肠镜。作者结论认为在此场景下不能推荐CCE。

要点

  • FIT阳性者中,研究组进展期肿瘤检出率0.67%,对照组0.64%,两组相似。
  • 研究组45.8%首选CCE,其中69.9%后续转诊结肠镜,导致二次结肠镜率很高。
  • 作者结论:在此高结肠镜依从性筛查场景下不能推荐CCE。

核心结论

  • 提供CCE作为结肠镜替代方案未显著改变进展期肿瘤检出率,也未提高FIT阳性后的 uptake,反而导致很高的二次结肠镜率,因此在此场景下不能推荐CCE。

研究设计与样本

  • 随机、意向性治疗试验,纳入丹麦结直肠癌筛查中FIT阳性参与者,研究组可选择CCE或结肠镜,对照组仅接受结肠镜。

主要发现

  • 共向396 676人发送473 684份邀请,62.6%返还检测,其中11 075份阳性(4.5%),两组间无显著差异。
  • FIT阳性者中结肠镜 uptake 对照组为91.1%,研究组为91.7%。
  • 研究组中45.8%首选CCE,11.4%首选结肠镜,42.8%无偏好并接受结肠镜。
  • 初始选择CCE者中69.9%后续转诊结肠镜。
  • 进展期肿瘤检出率研究组0.67% vs 对照组0.64%,两组相似。

临床怎么用

  • 原文结论认为在此筛查场景下不能推荐CCE。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colonoscopy is among the standard tests for colorectal cancer (CRC) screening. However, uptake varies, and alternatives such as colon capsule endoscopy (CCE) are available. The uptake and detection rate of clinically significant neoplasia with CCE, compared with colonoscopy, remain unclear in this setting. OBJECTIVE: The primary objective of this study was to compare the detection rates of advanced neoplasia between CCE and colonoscopy, using a pathway in which the study group could choose between the two procedures, while the control group was offered only colonoscopy. DESIGN: A randomised, intention-to-treat trial was conducted among Danish CRC screening participants who tested positive with a faecal immunochemical test (FIT). The trial compared the detection rate of advanced neoplasia (primary outcome) and the uptake rate of both approaches between the two arms. RESULTS: A total of 473 684 invitations were sent to 396 676 individuals, with 62.6% returning the test. Among them, 11 075 tests were positive (4.5%), with no significant differences between the two study groups. Among FIT-positive cases, the uptake for colonoscopy was 91.1% in the control arm and 91.7% in the study arm, where participants had a choice of methods. In the study arm, 45.8% preferred CCE, 11.4% preferred colonoscopy and 42.8% had no preference and underwent colonoscopy. Ultimately, 69.9% of patients who initially opted for CCE were later referred for colonoscopy. The rate of advanced neoplasia detection was similar between the groups: 0.67% in the study arm versus 0.64% in the control arm. CONCLUSION: Offering CCE as an alternative to colonoscopy did not significantly alter the detection rate of advanced neoplasia, nor did it increase uptake in a screening programme with high adherence to colonoscopy following a positive FIT test. Instead, it led to a very high rate of secondary colonoscopies. Therefore, CCE cannot be recommended in this setting. TRIAL REGISTRATION NUMBER: NCT04049357 (ClinicalTrials.gov).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Baatrup G, Bjørsum-Meyer T, Kaalby L, et al. Choice of colon capsule or colonoscopy versus default colonoscopy in FIT positive patients in the Danish screening programme: a parallel group randomised controlled trial. Gut. 2025. PMID: 40210462. doi:10.1136/gutjnl-2024-333687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。